Enhanced oxidative killing of azole-resistant Candida glabrata strains with ERG11 deletion

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 7, 1996, Pages 1717-1719

  Kan, Virginia L ^a   Geber, Antonia ^b,c,d   Bennett, John E ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^d CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; HYDROGEN PEROXIDE;

ARTICLE; CANDIDA GLABRATA; CANDIDIASIS; DRUG SENSITIVITY; GENE MUTATION; HUMAN; HUMAN CELL; NEUTROPHIL; OXIDATION; PHAGOCYTOSIS; PRIORITY JOURNAL; RESPIRATORY BURST; SURVIVAL RATE;

EID: 0029938197     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.7.1717     Document Type: Article

References (24)

1. Bard, M., N. D. Lees, T. Turi, D. Craft, L. Cotrin, R. Barbuch, C. Koegel, and J. C. Loper. 1993. Sterol synthesis and viability of erg11 (cytochrome P450 lanosterol demethylase) mutations in Saccharomyces cerevisiae and Candida albicans. Lipids 28:963-967.
2. Barr, C. E., and J. P. Torosian. 1986. Oral manifestations in patients with AIDS or AIDS-related complex. Lancet ii:288.
3. Boyum, A. 1968. Isolation of mononuclear cells and granulocytes from human blood. Scand. J. Clin. Lab. Invest. 97(Suppl.):77-89.
4. DeBrabander, M., F. Aerts, J. Van Cutsem, H. Vanden Bossche, and M. Borgers. 1980. The activity of ketoconazole in mixed cultures of leukocytes and Candida albicans. Sabouraudia 18:197-210.
5. Dixon, W. J., and F. J. Massey, Jr. 1969. Introduction to statistical analysis, 3rd ed. McGraw-Hill, New York.
6. Dupont, B., and E. Drouhet. 1988. Fluconazole in the management of oropharyngeal candidosis in a predominantly HIV antibody-positive group of patients. J. Med. Vet. Mycol. 26:67-71.
7. Geber, A., C. A. Hitchcock, J. E. Swartz, F. S. Pullen, K. E. Marsden, K. J. Kwon-Chung, and J. E. Bennett. 1995. Deletion of the Candida glabrata ERG3 and ERG11 genes: effect on cell viability, cell growth, sterol composition, and antifungal susceptibility. Antimicrob. Agents Chemother. 39: 2708-2717.
8. Hitchcock, C. A. 1993. Resistance of Candida albicans to azole antifungal agents. Biochem. Soc. Trans. 21:1039-1047.
9. Hitchcock, C. A., G. W. Pye, P. F. Troke, E. M. Johnson, and D. W. Warnock. 1993. Fluconazole resistance in Candida glabrata. Antimicrob. Agents Chemother. 37:1962-1965.
10. Iyer, G. Y. N., M. F. Islam, and J. H. Quastel. 1961. Biochemical aspects of phagocytosis. Nature (London) 192:535-541.
11. Klein, R. S., C. A. Harris, C. B. Small, B. Moll, M. Lesser, and G. H. Friedland. 1984. Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome. N. Engl. J. Med. 311: 356-357.
12. Lehrer, R. I. 1969. Antifungal effects of peroxidase systems. J. Bacteriol. 99:361-365.
13. Levitz, S. M. 1994. Overview of host defenses in fungal infections. Clin. Infect. Dis. 14(Suppl. 1):S37-S42.
14. Lindemann, R. A., and C. K. Franker. 1991. Phagocyte-mediated killing of Candida tropicalis. Mycopathologia 113:81-87.
15. McNeil, J., and V. Kan. 1995. Oral yeast colonization of HIV-infected outpatients. AIDS 9:301-302.
16. Minguez, F., M. L. Chiu, J. E. Lima, R. Nique, and J. Prieto. 1994. Activity of fluconazole: postantifungal effect, effects of low concentrations and of pretreatment on the susceptibility of Candida albicans to leukocytes. J. Antimicrob. Chemother. 34:93-100.
17. Newman, S. L., T. P. Flanigan, A. Fisher, M. G. Rinaldi, M. Stein, and K. Vigilante. 1994. Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS. Clin. Infect. Dis. 19:684-686.
18. Powderly, W. G. 1992. Mucosal candidiasis caused by non-albicans species of Candida in HIV-positive patients. AIDS 6:593-606.
19. Shigematsu, M. L., J. Uno, and T. Arai. 1981. Correlative studies on in vivo and in vitro effectiveness of ketoconazole against Candida albicans infection. Jpn. J. Med. Mycol. 22:195-201.
20. Shimokawa, O., and H. Nakayama. 1992. Increased sensitivity of Candida albicans cells accumulating 14α-methylated sterols to active oxygen: possible relevance to in vivo efficacies of azole antifungal agents. Amimicrob. Agents Chemother. 36:1626-1629.
21. Solomkin, J. S., E. L. Mills, G. S. Giebink, R. D. Nelson, R. L. Simmons, and P. G. Quie. 1978. Phagocytosis of Candida albicans by human leukocytes: opsonic requirements. J. Infect. Dis. 137:30-37.
22. Vanden Bossche, H., P. Marichal, F. C. Odds, L. Le Jeune, and M.-C. Coene. 1992. Characterization of an azole-resistant Candida glabrata isolate. Antimicrob. Agents Chemother. 36:2602-2610.
23. Watson, P. F., M. E. Rose, S. W. Ellis, H. England, and S. L. Kelly. 1989. Defective sterol C5-6 desaturation and azoic resistance: a new hypothesis for the mode of action of azoic antifungals. Biochem. Biophys. Res. Commun. 164:1170-1175.
24. Xhonneux, B., T. Jansen, M. Borgers, and F. C. Odds. 1992. Effects of itraconazole on phagocytosis and killing of Candida glabrata by polymorphonuclear leukocytes from guinea pigs. J. Antimicrob. Chemother. 30:181-188.